Indicated for: prevention of transplant rejection
Route of administration: infusion
Substance: belatacept (fusion protein)
ATC: L04AA28 (Antineoplastic and immunomodulating agents | Immunosuppressants | Selective immunosuppressants)
Belatacept is a medication used to prevent organ rejection in patients who have undergone kidney transplantation. It is an immunomodulatory agent that blocks costimulatory signaling required for T-cell activation, thereby reducing the immune response against the transplanted organ.
The medication is administered via intravenous infusion, usually once a month, as directed by a doctor. The treatment requires regular monitoring to assess kidney function and prevent infections.
Common side effects include anemia, infections, high blood pressure, and edema. In rare cases, more severe adverse effects such as post-transplant lymphoproliferative disorder or severe infections may occur.
Belatacept is not recommended for pregnant or breastfeeding women unless the benefits outweigh the risks. Patients should inform their doctor about all medications they are taking to avoid drug interactions.